Procept BioroboticsPRCT
PRCT
About: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Employees: 626
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 24
33% more capital invested
Capital invested by funds: $2.75B [Q2] → $3.65B (+$902M) [Q3]
24% more funds holding
Funds holding: 198 [Q2] → 246 (+48) [Q3]
15% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 71
0.55% more ownership
Funds ownership: 87.53% [Q2] → 88.08% (+0.55%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]
9% less call options, than puts
Call options by funds: $23.3M | Put options by funds: $25.7M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
10%
downside
Avg. target
$98
18%
upside
High target
$112
34%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Wells Fargo Nathan Treybeck 60% 1-year accuracy 3 / 5 met price target | 34%upside $112 | Overweight Reinstated | 3 Dec 2024 |
Morgan Stanley Patrick Wood 55% 1-year accuracy 6 / 11 met price target | 26%upside $105 | Overweight Initiated | 2 Dec 2024 |
Jefferies Michael Sarcone 100% 1-year accuracy 1 / 1 met price target | 14%upside $95 | Hold Initiated | 14 Nov 2024 |
Truist Securities Richard Newitter 74% 1-year accuracy 31 / 42 met price target | 26%upside $105 | Buy Reiterated | 30 Oct 2024 |
Piper Sandler Matt O'Brien 57% 1-year accuracy 29 / 51 met price target | 10%downside $75 | Overweight Reiterated | 8 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
Positive
Seeking Alpha
1 month ago
Procept BioRobotics: Continued Growth Runway Ahead
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage.
Positive
Zacks Investment Research
1 month ago
Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Investors Business Daily
1 month ago
Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook
Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Positive
Benzinga
1 month ago
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.
Neutral
Seeking Alpha
1 month ago
PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaway - Leerink Partners Operator Good morning and welcome to PROCEPT BioRobotics Third Quarter 2024 Earnings Conference Call. At this time all participants' are in a listen-only mode.
Positive
Investors Business Daily
1 month ago
Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise
Procept Biorobotics shares surged Monday after the robotic surgery player beat September-quarter expectations and hiked its outlook.
Charts implemented using Lightweight Charts™